Drug intelligence / Profile preview

camptothecin

Development stage
Unknown
Lead developer
National Cancer Institute
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

Camptothecin is a natural pentacyclic quinoline alkaloid originally isolated from the bark of Camptotheca acuminata (the "happy tree") native to China[2][5][7]. It is a potent inhibitor of DNA topoisomerase I, an enzyme essential for DNA replication and transcription. Camptothecin binds to the topoisomerase I-DNA complex, stabilizing it and preventing re-ligation of single-strand breaks in DNA. This leads to accumulation of DNA damage and ultimately induces apoptosis in rapidly dividing cells such as cancer cells[1][2][5]. Despite strong anticancer activity observed in preclinical studies and early clinical trials—especially against breast, ovarian, colon, lung, and stomach cancers—its clinical use has been limited by poor water solubility and severe adverse effects[1][2][5][7]. These limitations have led to the development of more soluble analogues such as irinotecan and topotecan that are widely used in cancer chemotherapy today[2][5].

Other names
20(S)-camptothecinCPT(S)-(+)-camptothecin
02

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on camptothecin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on camptothecin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call